Page 73 - Demo

321ANALESRANFwwwanalesranfcomActualizaciónentabaquismoabordajedesdelafarmaciacomunitariaytratamientosfarmacológicosdeelecciónMiguelCAguilóJuanolaAnRealAcadFarmVol88nº3(2022)·pp311-3212019;1141951-6955WalkerNHoweCGloverMMcRobbieHBarnesJNosaV,etalCytisine versusnicotine for smokingcessationNEngl J Med2014;3712353-6256CourtneyRJ McRobbieH TutkaP, WeaverNAPetrieD MendelsohnCP,etalEffectofcytisinevsvareniclineonsmokingcessationarandomizedclinicaltrialJAMA2021;32656-6457WalkerNSmithBBarnes JVerbiestMParagV,PokhrelSetal.CytisineversusvareniclineforsmokingcessationinNewZealandindigenousMãoriarandomizedcontrolledtrialAddiction2019;114344-5258Jiménez-RuizCARDeSimónGutiérrezRSignes-CostaMiñana JSellarésTorresJDíaz-MarotoMuñozJL,RiescoMirandaJAetalProtocoloasistencialclínico-psicológicoparaeltratamientodeltabaquismoconcitisinaPrevTab2021;23(4)139-14559FichatécnicadeTodacitan®15mg2021Consultadoel13/04/2022Disponibleenhttps://cimaaempses/cima/pdfs/es/ft/83407/FT_83407pdftadoel18/04/2022Disponibleenhttps://wwwsogaparinfo/wpcontent/content/ uploads/2016/12/12-Diagnostico-y-tratamiento-tabaquismo-SEPAR.pdf.pdf43MoolchanET,Robinson ML,Ernst MCadet JL,Pickworth WBHeishmanSJetalSafetyandefficacyofthenicotinepatchandgumfor the treatmentofadolescent tobaccoaddictionPediatrics2005;115(4)e407‐e414doi101542/peds2004-189444KrupskiL,CummingsKMHyland ACarlin-MenterS TollBAMahoneyMCNicotinereplacementtherapydistributiontolightdailysmokerscallingaquitlineNicotineTobRes2013;15(9)1572-1577doi101093/ntr/ntt02145GradySRDrenanRMBreiningSR YohannesD WagemanCRFedorovNBMcKinneySWhiteakerP,BencherifMLesterHAMarksMJStructuraldifferencesdeterminetherelativeselectivityofnicotiniccompoundsfornativealpha4beta2*-alpha6beta2*-alpha3beta4*-andalpha7-nicotineacetylcholinereceptorsNeuropharmacology2010Jun;58(7)1054-66doi101016/jneuropharm20100101346RollemaHHurstRSThecontributionofagonistandantagonistactivitiesofa4b2*nAChRligandstosmokingcessationefficacyaquantitativeanalysisofliteraturedataPsychopharmacology2018Sep;235(9)2479-2505doi101007/s00213-018-4921-947HonoratoJTabaquismoyfarmacologíaDiscursodeingresoenlaReial AcadèmiadeFarmàciadeCatalunyaGráficasCastueraPamplona201348AnthenelliRMBenowitzNL, WestRSt AubinL, McRae T,LawrenceDetalNeuropsychiatricsafetyandefficacyofvareniclinebupropionandnicotinepatchinsmokerswithawithoutpsychiatricdisorders(EAGLES)adouble-blindrandomisedplacebo-controlledclinicaltrialLancet2015;387(10037)2507-2049Prochaska JJDasSBenowitzNLCytisine the worldsoldestsmokingcessationaidBMJ2013;347f5198doi101136/bmjf519850Jiménez-RuizCACiceroGuerreroACristóbalFernándezMVillarLagunaCCitisinanuevofármacoparadejardefumarenEspañaPrevTab2021;23(2)58-6451WestR Zatonski W,Cedzynska MLewandowskaDPazik J AveyardP,etalPlacebo-controlled trialofcytisine forsmokingcessationNEnglJMed2011;3651193-20052HajekP,McRobbieHMyersKEfficacyofcytisineinhelpingsmokersquitsystematicreviewandmeta-analysisThorax2013;681037-4253CahillK,Lindson-HawleyNThomasKHFanshaweTRLancasterTNicotinereceptorpartialagonists for smokingcessationCochraneDatabaseSystRev2016;(5)CD00610354TutkaP,VinnikovDCourtneyRJBenowitzNLCytisine fornicotineaddictiontreatmentAreviewofpharmacology,therapeuticsandanupdateofclinical trialevidence for smokingcessation AddictionSideseacitarnuestroartículoActualizaciónentabaquismoabordajedesdelafarmaciacomunitariaytratamientosfarmacológicosdeelecciónMiguelCAguilóJuanolaAnRealAcadFarmInternetAnRealAcadFarmVol88nº3(2022)·pp311-321DOIhttp//dxdoiorg/1053519/analesranf2022880305